Background
==========

Diabetes is a disorder of the metabolism of carbohydrates, lipids and proteins in which the body cannot produce insulin or cannot use it to its full potential. Over 135 million people are affected by diabetes worldwide \[[@B1]\]. Diabetes can cause long-term complications such as retinopathy, neuropathy and nephropathy, and people with diabetes are at higher risk of myocardial infarction, stroke and limb amputation. Diabetes therapy is centered upon the control of blood glucose levels. Management of hyperglycemia with few side effects remains a challenge to the medical system.

*Rhuzima Coptidis* was recorded as an anti-diabetes medication approximately 1500 years ago in a book titled "Note of Elite Physicians" by Hongjing Tao. Berberine is the major active component of *Rhizoma coptidis*, and many studies have been published on the glucose reducing mechanisms of berberine. Zhou et al. found that berberine stimulated glucose transport through a mechanism distinct from insulin in 3T3-L1 adipocyes \[[@B2]\]. Moreover, berberine could activate AMPK and induced glycolysis in L6, C2C12, and 3 T3-L1 cell lines \[[@B3]\]. Additionally, berberine dose-dependently inhibited respiration in L6 myotubes through its specific effect on the respiratory complex I \[[@B4]\].

Berberine has beneficial properties in lipid and glucose metabolism regulation and has been effectively used in the treatment of diabetes, obesity and hypercholesterolemia. However, berberine has a low bioavailability \[[@B5]\], which is attributed to its poor aqueous solubility and dissolution.

Thus, we hypothesized that berberine can change gene expression in the intestine directly to moderate lipid and glucose metabolism. To understand the exact mechanisms, we used a type 2 diabetes rat model to investigate differential expression of genes in the intestine.

Methods
=======

Animal modeling, groups, and treatment
--------------------------------------

Male Sprague--Dawley rats (280--320 g) were purchased from the Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Peking Union Medical College (Beijing, China, SCXK-2012- 0007). According to a previous study \[[@B6]\] diabetic rats were fed a high-fat diet (40% of calories as fat) for 4 weeks and then administered with a single dose of streptozotocin (STZ, 50 mg/kg, tail vein) formulated in 0.1 mmol/l citrate buffer, pH 4.5 (Sigma-Aldrich, Germany). One week after the STZ injection, the random blood glucose levels of the diabetic rats were measured to confirm hyperglycemia. Random blood glucose measurements above 16.7 mmol/l were used to define rats as diabetic. Diabetic rats were fed a high-fat diet throughout the experiment. Diabetic rats with a similar degree of hyperglycemia were randomly divided into three groups: vehicle, low dose berberine (BerL), and high dose berberine (BerH) groups (n = 8, in each group). The typical human daily dose of berberine is 1200 mg/60 kg body weight. According to the formula: d~rat~ = d~human~ X 0.71/0.11 \[[@B7]\], the corresponding dose of berberine for rats is 129.09 mg/kg per day, so we selected 120 mg/kg and 240 mg/kg per day as low and high dosages, respectively. The control (n = 8) and vehicle group received 0.5% saline, whereas the BerL and BerH groups were given berberine at 120 mg/kg and 240 mg/kg in 0.5% saline, respectively. The drug was administered once daily for 8 weeks using a gastric gavage. All animals were housed in an environmentally controlled room at 25°C in a 12 h light: 12 h darkness cycle and given free access to food and water throughout the experimental period. Fasting animals were allowed free access to water. After 6 weeks of treatment, an oral glucose tolerance test (OGTT) was performed. After 8 weeks of treatment, blood samples were taken from the rats after anesthesia. The rats were then sacrificed. Some terminal ileum sample was collected to perform the microarray and quantitative real-time PCR (qRT-PCR) experiments. Some terminal ileum sample was fixed in 10% neutralized formalin for immunohistochemical staining. All procedures involving animals were approved by the animal care and use committee of the Peking Union Medical College Hospital (Beijing, China, MC-07-6004) and were conducted in compliance with the Guide of the Care and Use of Laboratory Animals (NIH publication No. 86-23, revised 1996). All surgeries were performed under sodium pentobarbital anesthesia, and all efforts were made to minimize suffering.

Measurement of body weight and fasting blood glucose levels
-----------------------------------------------------------

Body weight was monitored every 2 weeks. The 6-h fasting blood glucose (FBG) level was measured monthly using the enzyme end-point method (Roche, Germany) with blood from a tail bleed.

Oral glucose tolerance test (OGTT)
----------------------------------

After the rats fasted for 6 h, 2.2 g/kg of glucose was orally administered. Then, blood samples were collected from tail veins at 0 min (prior to glucose load), 30 min, 60 min, and 120 min (after glucose load) for the glucose assay. The area under the curve (AUC) was calculated for blood glucose during the OGTT using the following equation: AUC = 0.5 × (BG0 + BG30)/2 + 0.5 × (BG30 + BG60)/2 + 1 × (BG60 + BG120)/2, where BG is blood glucose.

Serum biochemistry analysis
---------------------------

At week 6, after the rats fasted for 6 h, the animals were euthanized. Rats received 2.2 g/kg of glucose by gavage, then the abdominal cavity was opened and a canula was inserted in the portal vein. Before the glucose load, some blood samples were taken and then centrifuged at 1000 g for 10 min. Serum was stored in aliquots at -80°C for an assay of serum fasting insulin. At 15 min following the glucose load, portal blood samples were collected in EDTA tubes containing dipeptidyle peptidase IV inhibitor (10 μL/mL blood sample, Millipore, MA, USA) via the portal vein. Plasma samples were obtained and stored at -80°C for assessment of glucagon-like peptide-1 (GLP-1). Serum insulin and plasma active GLP-1 (i.e., GLP-1 \[7-36 amide\] and GLP-1 \[7-37\]) was measured with an ELISA (Millipore, USA). HOMA-IR = FBG (mmol/L) × FINS (μU/mL)/22.5.

RNA preparation and whole-genome gene expression profiling array experiments
----------------------------------------------------------------------------

The terminal ileum was taken from the BerH group and DM group (n = 3, in each group) to perform the microarray experiments. We selected the Rat 12 × 135 K Gene Expression Array which was manufactured by Roche NimbleGen (Germany). This array includes approximately 26,420 genes. Before the microarray experiment, total RNA was harvested using TRIzol (Invitrogen, CA, USA) and an RNeasy kit (Qiagen, Valencia, CA, USA) according to the manufacturer's instructions. Total RNA from each sample was quantified by the NanoDrop ND-1000 and RNA integrity was assessed by standard denaturing agarose gel electrophoresis. The total RNA of each sample was labeled using a NimbleGen One-Color DNA labeling kit and hybridized in a NimbleGen Hybridization System. After hybridization and washing, the processed slides were scanned with an Axon GenePix 4000B microarray scanner (Molecular Devices Corporation, USA). The microarray experiment was independently repeated in triplicate.

Gene array data analysis
------------------------

The data files were imported into Agilent GeneSpring Software (Agilent, version 11.0, USA) for analysis. The gene expression level in the BerH group was normalized to that in the DM group. Differentially expressed genes were identified through Fold Change and *t*-test *P*-value screening.

To assign biological meaning to the group of genes with changed expression, the subset of genes that met the above criteria was analyzed with the Gene Ontology (GO) classification system, using Database for Annotation, Visualization, and integrated Discovery (DAVID) software ([http://http:david.abcc.ncifcrf.gov/](http://http:david.abcc.ncifcrf.gov/)) \[[@B8]\] as well as the Kyoto Encyclopedia of Genes and Genomes (KEGG). All thresholds in our analyses were set to 0.001. Over-representation of genes with altered expression within specific GO categories was determined using the one-tailed Fisher exact probability modified by the addition of a jack-knifing procedure, which penalizes the significance of categories with very few (*eg.* one or two) genes and favors more robust categories with larger numbers of genes \[[@B9]\].

Quantitative real time PCR analysis
-----------------------------------

For validation of the microarray results, quantitative real time PCR (Q-RT-PCR) analyses were performed using SYBR Green. Each Q-RT-PCR assay was repeated using three biological replicates and each analysis consisted of three technical replicates. Before PCR, each total RNA was processed with RNase-free DNase (Qiagen, Valencia, CA, USA). RNA was reverse transcribed by Superscript II (Invitrogen, CA, USA). The primers were designed using Applied Biosystems (Foster City, CA, USA) Primer Express™ design software. Primers were purchased from Applied Biosystems (Table [1](#T1){ref-type="table"}). The reaction production could be accurately measured in the exponential phase of amplification by the ABI prism 7700 Sequence Detection System, with the following cycling conditions: an initial denaturation at 48°C for 30 min, 95°C for 15 min, 40 cycles of 95°C for 15 sec, 55°C for 1 min, and a final unlimited 4°C hold. The sequences of the primers used are listed in Table [1](#T1){ref-type="table"}. The signal of the housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (*Gapdh*) was used for normalization. Relative quantification of the mRNA between BerL, BerH and DM rats was calculated with the comparative Ct method \[[@B10]\].

###### 

Olgonucleotide sequences for Q-PCR

  **Gene symbol**   **Forward primer**      **Reverse primer**
  ----------------- ----------------------- -----------------------
  *Glp1r*           CATCGTGGTATCCAAACTGA    GCTCGTCCATCACAAAGG
  *Gnrh1*           TGGTATCCCTTTGGCTTTCA    TCCTCCTCCTTGCCCATCTC
  *Gnrhr*           TTGTTGATGGCTGAGCAGTGA   AAGCCCGTCCTTGGAGGAAAT
  *Mapk10*          TCGAGACCGTTTCAGTCCAT    CCACGGACCAAATATCCACT
  *Gadph*           GACCCCTTCATTGACCTCAAC   CGCTCCTGGAAGATGGTGATG

*Glp1r*: glucagon-like peptide 1 receptor; *Gnrh1*: gonadotropin releasing hormone 1; *Gnrhr*: gonadotropin releasing hormone receptor; *Mapk10*: mitogen activated protein kinase 10.

Immunohistochemical straining
-----------------------------

Ileum samples from the BerH and DM groups (n = 6 in each group) were fixed in 10% neutral buffered formalin, cast in paraffin, sliced into 4-μm sections and placed onto microscope slides. After the removal of the paraffin by xylene and dehydration by graded alcohol, the slides were immersed into distilled water. Ileum sections were then transferred into a 10 mmol/L citrate buffer solution (pH 6.0) and heated at 80°C for 5 min for antigen retrieval. After washing, 3.0% peroxide was applied for 20 min to block the activity of endogenous peroxidase. To avoid nonspecific staining, the sections were incubated in blocking solution (5% BSA, Sigma, Germany) for 1 h at room temperature, followed by treatment with rabbit polyclonal anti-GLP1R antibody (1:100, Abcam lnc., UK), or rabbit polyclonal anti-MAPK10 antibody (1:100, Abcam Inc., UK), where indicated, overnight at 4°C. Negative control sections were stained under identical conditions by substituting the primary antibody with equivalent concentrations of normal rabbit IgG. After washing with phosphate-buffered saline, the slides were incubated with a labeled streptavidin biotin reagent, following the manufacturer's instructions. Immunoreactive products were visualized with the DAB reaction. Sections were counterstained with hematoxylin for 15 sec. Brownish yellow granular or linear deposits were interpreted as positive areas. Three observers who were blinded to the clinical information evaluated the immunohistochemical staining scores independently. Staining intensity was graded semi-quantitatively using the H-SCORE \[[@B11]\], which was calculated using the following equation: H-SCORE = ∑Pi (i + 1), where i is the intensity of staining with a value of 1, 2 or 3 (mild, moderate, or strong, respectively) and Pi is the percentage of epithelial cells stained with different intensity, varying from 0% to 100%. The results are expressed as the mean ± SE. Differences between the groups were statistically analyzed with a one-way analysis of variance (ANOVA). A *P* value of \< 0.05 was considered significant.

Statistical analysis
--------------------

All results are expressed as the mean ± standard deviation (SD). Statistical analyses were performed with analysis of variance followed by Student's *t-*test. *P* \< 0.05 was considered statistically significant. Analysis was done with SPSS 11.0 (SPSS, Inc., Chicago, IL, USA).

Results
=======

Berberine showed no effect on body weight of DM rats
----------------------------------------------------

The mean body weight of diabetic rats was significantly decreased compared to the control rats at week 2 (*P* \< 0.05), week 4 (*P* \< 0.01), week 6 (*P* \< 0.01) and week 8 (*P* \< 0.01). No significant differences were noted between the DM group and berberine-treated groups (Figure [1](#F1){ref-type="fig"}A).

![**The body weight (A) and fasting blood glucose (B) before and after berberine treatment in the rats (n = 8, in each group).** Data represent mean ± S. D. (n = 8). \**P* \< 0.05, \*\**P* \< 0.01 versus the control group; \#*P* \< 0.05 versus DM group.](1472-6882-14-188-1){#F1}

Berberine decreased fasting blood glucose of DM rats
----------------------------------------------------

The fasting blood glucose (FBG) levels of DM rats and the BerL group and BerH group were significantly higher than those of control rats at week 0 (*P* \< 0.01), week 2 (*P* \< 0.01), week 4 (*P* \< 0.01), week 6 (*P* \< 0.01) and week 8 (*P* \< 0.01). FBG in the BerL group and BerH group decreased significantly at week 2 (*P* \< 0.05), week 4 (*P* \< 0.05), week 6 (*P* \< 0.05) and week 8 (*P* \< 0.05) compared to the DM group (Figure [1](#F1){ref-type="fig"}B).

Berberine moderated the glucose tolerance of DM rats
----------------------------------------------------

The blood glucose levels of the DM, BerL and BerH groups were higher than those of the control group before (0 min, *P* \< 0.01) and at 30 min (*P* \< 0.01), 60 min (*P* \< 0.01) and 120 min (*P* \< 0.01) after oral glucose administration. Blood glucose levels of the BerL and BerH groups significantly decreased before (0 min, *P* \< 0.05) and after oral glucose administration (*P* \< 0.05 all above, Figure [2](#F2){ref-type="fig"}A). The AUC of OGTT for the DM, BerL and BerH groups increased compared to the control group (*P* \< 0.05). The AUC for the BerL and BerH groups reduced compared with the DM group (*P* \< 0.05, Figure [2](#F2){ref-type="fig"}B).

![**The effect of berberine on oral glucose tolerance test blood glucose (A) and AUC (B) in rats (n = 8, in each group).** Data represent mean ± S. D. (n = 8). \*\**P* \< 0.01 versus the control group; \#*P* \< 0.05 versus DM group.](1472-6882-14-188-2){#F2}

Berberine reduced FINS and HOMA-IR in DM rats
---------------------------------------------

FINS and HOMA-IR levels of the DM rats were significantly elevated (*P* \< 0.01) after 8 weeks of treatment and berberine significantly suppressed FINS (*P* \< 0.05) and HOMA-IR (*P* \< 0.01, Figure [3](#F3){ref-type="fig"}A and B).

![**The effect of berberine on serum fasting insulin (A), HOMA-IR (B) and plasma postprandial GLP-1 (C) in rats (n = 8, in each group).** Data represent mean ± S. D. (n = 8). \*\**P* \< 0.01 versus the control group; \# *P* \< 0.05, \#\#*P* \< 0.01 versus DM group.](1472-6882-14-188-3){#F3}

Berberine increased GLP-1 in DM rats
------------------------------------

Plasma postprandial GLP-1 levels in the BerH group were increased to the DM group (Figure [3](#F3){ref-type="fig"}C).

Genes differentially regulated by berberine
-------------------------------------------

There were 2,112 differentially expressed genes identified in the terminal ileum between the BerH group and DM group. Of those, 780 genes (36.9%) were up-regulated and 1,332 genes (63.1%) were down-regulated in the BerH group.

The aforementioned DAVID annotation tool was used for identification of GO and putative KEGG pathways. DAVID analysis of all the differentially expressed genes yielded 55 GO categorues (FDR\<0.001, Table [2](#T2){ref-type="table"}). The genes were mapped to 9 pathways (FDR \< 0.001, Table [3](#T3){ref-type="table"}). Two of the most common types of enriched pathways were the MAPK signaling pathway (FDR = 3.26E-19) and the GnRH signaling pathway (FDR = 1.01E-13). In the MAPK signaling pathway, in particular, 266 genes were represented on the gene array, of which 95 genes were differentially expressed.

###### 

Gene ontology groups with significant over-representation among genes with significantly changed expression in the BerH (FDR \< 0.001)

  **GO classification**                              **Go term**                       **GO ID**    **Count**   **Fold enrichment**   **FDR**
  -------------------------------------------------- --------------------------------- ------------ ----------- --------------------- ----------
  Biological process                                 Intracellular signaling cascade   GO:0007242   60          7.195                 1.61E-18
  Phosphate metabolic process                        GO:0006796                        55           7.186       1.06E-17              
  Phosphorus metabolic process                       GO:0006793                        55           7.169       1.20E-17              
  Protein kinase cascade                             GO:0007243                        34           14.126      7.10E-16              
  Regulation of phosphorylation                      GO:0042325                        37           10.287      1.03E-15              
  Regulation of phosphate metabolic process          GO:0019220                        37           9.890       4.11E-15              
  Regulation of phosphorus metabolic process         GO:0051174                        37           9.890       4.11E-15              
  Protein amino acid phosphorylation                 GO:0006468                        42           7.539       2.09E-14              
  Regulation of kinase activity                      GO:0043549                        32           12.455      2.41E-14              
  Regulation of transferase activity                 GO:0051338                        32           11.872      1.06E-13              
  Response to organic substance                      GO:0010033                        48           5.738       2.16E-13              
  Regulation of protein kinase activity              GO:0045859                        30           12.280      1.81E-12              
  Phosphorylation                                    GO:0016310                        42           6.516       5.62E-12              
  MAPKKK cascade                                     GO:0000165                        24           18.618      9.75E-12              
  Positive regulation of kinase activity             GO:0033674                        26           14.494      5.94E-11              
  Positive regulation of transferase activity        GO:0051347                        26           13.866      1.81E-10              
  Response to endogenous stimulus                    GO:0009719                        37           7.163       2.64E-10              
  Positive regulation of molecular function          GO:0044093                        34           7.439       6.39E-09              
  Positive regulation of protein kinase activity     GO:0045860                        24           13.939      8.79E-09              
  Positive regulation of catalytic activity          GO:0043085                        32           7.995       1.47E-08              
  Response to hormone stimulus                       GO:0009725                        33           7.178       8.01E-08              
  Regulation of apoptosis                            GO:0042981                        32           5.243       2.47E-06              
  Regulation of programmed cell death                GO:0043067                        32           5.174       3.54E-06              
  Regulation of cell death                           GO:0010941                        32           5.152       4.01E-06              
  Activation of protein kinase A activity            GO:0034199                        9            66.561      3.21E-05              
  Enzyme linked receptor protein signaling pathway   GO:0007167                        21           8.320       7.94E-05              
  Regulation of MAP kinase activity                  GO:0043405                        15           14.469      2.47E-04              
  Cellular response to hormone stimulus              GO:0032870                        16           12.588      2.76E-04              
  Negative regulation of catalytic activity          GO:0043086                        19           9.007       3.78E-04              
  cAMP biosynthetic process                          GO:0006171                        8            73.957      4.80E-04              
  Activation of protein kinase activity              GO:0032147                        14           15.687      6.06E-04              
  Cellular constituent                               Cytosol                           GO:0005829   46          4.618                 4.08E-17
  Cell fraction                                      GO:0000267                        32           3.714       9.48E-08              
  Nucleoplasm                                        GO:0005654                        25           4.037       5.43E-06              
  Insoluble fraction                                 GO:0005626                        25           3.716       2.73E-05              
  Soluble fraction                                   GO:0005625                        16           6.026       5.40E-05              
  Organelle lumen                                    GO:0043233                        31           2.849       1.12E-04              
  Plasma membrane                                    GO:0005886                        45           2.108       1.93E-04              
  Membrane-enclosed lumen                            GO:0031974                        31           2.772       2.06E-04              
  Nuclear lumen                                      GO:0031981                        26           3.148       3.24E-04              
  Intracellular organelle lumen                      GO:0070013                        28           2.668       0.002417965           
  Molecular function                                 Protein kinase activity           GO:0004672   38          7.617                 4.54E-12
  Purine ribonucleotide binding                      GO:0032555                        53           3.841       1.29E-11              
  Ribonucleotide binding                             GO:0032553                        53           3.839       1.33E-11              
  Protein serine/threonine kinase activity           GO:0004674                        30           8.615       2.66E-11              
  Purine nucleotide binding                          GO:0017076                        53           3.660       1.11E-10              
  ATP binding                                        GO:0005524                        46           4.169       6.83E-10              
  Adenyl ribonucleotide binding                      GO:0032559                        46           4.087       1.47E-09              
  Adenyl nucleotide binding                          GO:0030554                        46           3.856       1.44E-08              
  Purine nucleoside binding                          GO:0001883                        46           3.789       2.78E-08              
  Nucleoside binding                                 GO:0001882                        46           3.759       5.66E-08              
  Nucleotide binding                                 GO:0000166                        53           3.059       3.25E-07              
  MAP kinase activity                                GO:0004707                        9            59.748      7.78E-06              
  Adenylate cyclase activity                         GO:0004016                        8            82.079      1.34E-05              
  Phosphoprotein phosphatase activity                GO:0004721                        15           13.329      5.76E-05              
  Kinase binding                                     GO:0019900                        16           10.031      5.56E-04              

###### 

KEGG pathway (FDR \< 0.001, Fold enrichment \> 2.0)

  **KEGG_ID**   **Term**                            **Count**   **Total number of genes in the pathway**   **Fold enrichment**   **FDR**    **Genes**
  ------------- ----------------------------------- ----------- ------------------------------------------ --------------------- ---------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  rno04010      MAPK signaling pathway              95          266                                        17.985                3.26E-19   RGD1565395, HRAS, PDGFA, TGFB3, NFKB1, FGF12, NFKB2, DAXX, TGFB1, TGFB2, AKT1, CDC42, FOS, CASP3, MOS, RRAS, PRKACA, PRKACB, FAS, MAP2K7, AKT3, AKT2, MAP2K5, EGFR, PRKCA, RELA, PTPRR, TP53, FLNC, ECSIT, FLNB, PRKCB, MAPK1, MAP4K4, RASGRF1, JUN, MAPK3, PDGFRA, HSPB1, MAPK9, PDGFRB, MAPK8, MAP3K14, GADD45A, FGFR2, FGFR1, TRAF2, GRB2, MRAS, MAPKAPK5, MKNK2, DUSP10, ELK1, HSPA1A, HSPA1B, MAPKAPK2, HSPA1L, TNFRSF1A, HSPA2, ELK4, SOS1, SOS2, DUSP16, RAC1, PPP3CB, PPP3CC, PPP3CA, CHP, HSPA8, PTPN7, MAP2K1, MAP2K2, PTPN5, MAP2K3, NLK, MAP2K4, TAOK3, NR4A1, RAF1, MAPK10, DUSP5, NRAS, DUSP4, DUSP3, ATF4, DUSP2, DUSP1, MAPK14, NTRK2, IKBKG, MAPK8IP3, DUSP9, IKBKB, CRK, DUSP7, DUSP6
  rno04912      GnRH signaling pathway              42          94                                         22.501                1.01E-13   ADCY3, ADCY4, ADCY1, HRAS, ADCY2, ADCY7, GRB2, ADCY5, GNA11, ADCY6, ELK1, GNRHR, MMP2, CDC42, PTK2B, SOS1, SOS2, PRKACA, PRKACB, MAP2K7, EGFR, PRKCA, GNRH1, MAP2K1, MAP2K2, MAP2K3, MAP2K4, RAF1, MAPK10, MMP14, PRKCD, PRKCB, MAPK1, NRAS, ATF4, GNAQ, ADCY9, JUN, MAPK14, MAPK3, MAPK9, MAPK8
  rno04540      Gap junction                        29          81                                         18.030                9.06E-11   ADCY3, ADCY4, ADCY1, HRAS, ADCY2, ADCY7, PDGFA, GRB2, ADCY5, GNA11, ADCY6, SOS1, SOS2, PRKACA, PRKACB, MAP2K5, PRKCA, EGFR, MAP2K1, MAP2K2, RAF1, PRKCB, NRAS, MAPK1, ADCY9, GNAQ, MAPK3, PDGFRA, PDGFRB
  rno04722      Neurotrophin signaling pathway      31          126                                        12.390                2.14E-09   HRAS, GRB2, NFKB1, MAPKAPK2, AKT1, CDC42, SOS1, RAC1, SOS2, MAP2K7, AKT3, AKT2, MAP2K5, MAP2K1, MAP2K2, RELA, TP53, RAF1, MAPK10, PRKCD, NRAS, MAPK1, ATF4, JUN, MAPK14, MAPK3, NTRK2, MAPK9, MAPK8, IKBKB, CRK
  rno05200      Pathways in cancer                  43          317                                        6.831                 4.57E-08   FGFR2, TRAF2, FGFR1, HRAS, PDGFA, GRB2, TGFB3, NFKB1, FGF12, NFKB2, MMP2, TGFB1, TGFB2, AKT1, CDC42, FOS, CASP3, SOS1, SOS2, RAC1, FAS, AKT3, AKT2, EGFR, PRKCA, MAP2K1, MAP2K2, RELA, TP53, RAF1, MAPK10, PRKCB, MAPK1, NRAS, JUN, IKBKG, MAPK3, PDGFRA, PDGFRB, MAPK9, MAPK8, IKBKB, CRK
  rno04662      B cell receptor signaling pathway   25          75                                         16.786                9.81E-07   HRAS, GRB2, NFKB1, AKT1, FOS, SOS1, RAC1, SOS2, PPP3CB, PPP3CC, CHP, PPP3CA, AKT3, AKT2, MAP2K1, MAP2K2, RELA, RAF1, PRKCB, NRAS, MAPK1, JUN, MAPK3, IKBKG, IKBKB
  rno04660      T cell receptor signaling pathway   28          109                                        12.936                2.43E-06   HRAS, GRB2, NFKB1, AKT1, CDC42, FOS, SOS1, SOS2, PPP3CB, PPP3CC, PPP3CA, CHP, MAP2K7, AKT3, AKT2, MAP2K1, MAP2K2, RELA, RAF1, NRAS, MAPK1, JUN, MAPK14, IKBKG, MAPK3, MAPK9, IKBKB, MAP3K14
  rno04062      Chemokine signaling pathway         32          171                                        9.424                 2.04E-05   ADCY3, ADCY4, ADCY1, HRAS, ADCY2, ADCY7, GRB2, ADCY5, ADCY6, NFKB1, AKT1, CDC42, PTK2B, SOS1, SOS2, RAC1, PRKACA, PRKACB, AKT3, AKT2, MAP2K1, RELA, RAF1, PRKCD, PRKCB, NRAS, MAPK1, ADCY9, IKBKG, MAPK3, IKBKB, CRK
  rno05215      Prostate cancer                     25          90                                         13.988                1.32E-04   FGFR2, FGFR1, HRAS, PDGFA, GRB2, NFKB1, AKT1, SOS1, SOS2, AKT3, AKT2, EGFR, MAP2K1, MAP2K2, RELA, TP53, RAF1, NRAS, MAPK1, ATF4, IKBKG, MAPK3, PDGFRA, PDGFRB, IKBKB

Immunohistochemical staining
----------------------------

To confirm that protein expression in the GLP1R and MAPK pathways was altered in the ileum of DM rats treated with berberine, immunohistochemistry analyses for GLP1R and MAPK10 were performed on ileum tissues. In the BerH group, there was a statistically significant increase in the immunoreactivities of GLP1R and MAPK10 (Figure [4](#F4){ref-type="fig"}).

![**The iluem immunohistochemistry for GLP1R and MAPK10 expression (original magnification × 200) and semiquantitative assessments.A**-**B** Immunostaining for GLP1R. **C**-**D** immunostaining for MAPK10. Iluem were harvested form DM **(A, C)** and berH group **(B, D)**. **(E)** Semiquatitatve scores of GLP1R and MAPK10. Data represent mean ± SD (n = 6). \#*P* \< 0.05 versus DM group.](1472-6882-14-188-4){#F4}

Q-RT-PCR experiment
-------------------

We used Q-RT-PCR assays to verify some of the microarray results. Four genes \[Glucagon-like peptide 1 receptor (Glp1r), gonadotropin-releasing hormone 1 (Gnrh1), gonadotropin releasing hormone receptor (Gnrhr) and mitogen activated protein kinase 10 (Mapk10)\] were selected for verification, because of their central positions in the MAPK signaling pathway and GnRH signaling pathway. The expression ratios of these four genes, as determined through microarrays and Q-RT-PCR, are shown in Table [4](#T4){ref-type="table"}. Glp1r and Mapk10 were up-regulated; while Gnrhr and Gnrh1 were down-regulated in both of the BerL group and BerH group. Strong agreement between the microarray and Q-RT-PCR results was observed for both genes, indicating the reliability of our microarray assays.

###### 

Fold change in gene expression measured by gene array and Q-RT-PCR

  **Gene symbol**    **BerL vs DM**  **BerH vs DM**                                 
  ----------------- ---------------- ---------------- ------- -------- ------------ -------
  *Glp1r*                3.862       4.6 ± 0.3        0.027    4.231   4.3 ± 0.2    0.026
  *Gnrh1*                −4.615      −3.7 ± 0.2       0.038    −3.758  −3.5 ± 0.3   0.025
  *Gnrhr*                −3.715      −3.1 ± 0.4       0.014    −3.271  −2.9 ± 0.4   0.039
  *Mapk10*               6.362       5.9 ± 0.3        0.031    5.837   6.2 ± 0.5    0.015

*Glp1r*: glucagon-like peptide 1 receptor; *Gnrh1*: gonadotropin-releasing hormone 1; *Gnrhr*: gonadotropin releasing hormone receptor; *Mapk10*: mitogen activated protein kinase 10.

Each Q-RT-PCR assay was repeated using three biological replicates and each analysis consisted of three technical replicates.

Discussion
==========

In this study, we found that the administration of berberine to diabetic rats significantly reduced fasting blood glucose, moderated glucose tolerance and reduced serum insulin. These results suggest that berberine can moderate glucose metabolism and ameliorate oral glucose tolerance and insulin sensitivity. These results are similar to the results of other studies \[[@B12]-[@B16]\].

Moreover, we found that berberine increased plasma GLP-1 after an oral glucose load. GLP-1 is a gut derived hormone secreted from intestinal L cells in response to glucose \[[@B17]\]. GLP-1 exerts important effects on the regulation of glucose metabolism, stimulating glucose-dependent insulin secretion and promoting β cell proliferation \[[@B18]\]. At the same time, GLP-1 inhibits glucagon release, gastric emptying and food intake \[[@B19]\]. Berberine may increase GLP-1 (7-36) amide secretion in STZ-induced diabetic rats \[[@B20]\], even in normal SD rats \[[@B21]\]. Recently, Shan et al. found that berberine could increase GLP-2 in type 2 diabetic rats \[[@B22]\].

We found that berberine could increase the expression of *Glp1r* in gene array experiments and Q-PCR experiments. Camilleri et al. found that GLP-1 can suppress gastrointestinal movement \[[@B23]\]. Furthermore, Feng et al. found that berberine could inhibit myoelectrical activity and gastrointestinal transit in rodents \[[@B21]\]. Therefore, berberine can increase plasma GLP-1 levels and Glp-1r expression to suppress gastrointestinal movement, moderate insulin secretion, and therefore moderate glucose metabolism.

In KEGG analysis, we found that the significant pathway in the berberine-treated group was the MAPK signaling pathway. Q-RT-PCR verified this result. TNF-α is interconnected with MAPK pathways. Waetzig et al. found that SB203580, a p38 inhibitor, significantly reduced mucosa secretion of TNF-α \[[@B24]\]. Hollenbach et al. found that SB203580 can reduce the mRNA levels of proinflammatory cytokines (i.e., TNF-α, IL-2 and IL-18) in the gut of BALB/c mice \[[@B25]\].

The GnRH signaling pathway was the second pathway in KEGG analysis. Q-PCR experiments also showed Gnrh1 and Gnrhr was reduced in the BerH group. Gonadotropin-releasing hormone (GnRH) and its receptor were expressed in the rat gastrointestinal system, pancreas and submaxillary glands, and its receptor had the same mRNA sequence with that of the hypothalamus, which demonstrated that GnRH was a brain-gut peptide \[[@B26],[@B27]\]. Intestinal GnRH had a regulatory role on the endocrine and exocrine functions of the digestive system. GnRH and its receptor were also expressed in glucagon-immunoreactive cells of the rat ileum. GnRH analogs had a regulatory role on intestinal glucagon-like immunoreactivity \[[@B28]\]. A focused literature review showed GnRH agonists could increase the weight and fat mass and insulin resistance syndrome in men. These results indicate that GnRH may increase the risk of diabetes mellitus \[[@B29]\]. In premenopausal women with symptomatic uterine leiomyomas, GnRH agonists also increased insulin levels and HOMA scores \[[@B30]\]. Moreover, Antide, a GnRH receptor antagonist, administration prevented an increased incidence of diabetes in a castrated male nonobese mouse model of autoimmune diabetes (NOD) mice \[[@B31]\]. In addition, GnRH modulates the expression of insulin in the NOD mouse independently of gonadal steroids. These results demonstrated that GnRH could inhibit insulin secretion by islet cells *in vitro* experiments \[[@B32]\]. Thus, berberine may moderate blood glucose and insulin secretion through decreasing activity of GnRH.

Conclusion
==========

In conclusion, our studies provide evidence that berberine reduces blood glucose and insulin in diabetic rats. The mechanism may be within the MAPK pathway and GnRH-GLP-1 pathway in the ileum. These results provide molecular information for further investigation of the mechanisms by which berberine moderates glucose metabolism. Furthermore, these results could be important in devising mechanism-based and targeted therapeutic strategies for diabetes. More experiments should been performed in the future to confirm these results (such as studying gastrointestinal movement and use of Western blot analysis).
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